Health Catalyst, Inc. (NASDAQ:HCAT) Receives $9.27 Average Price Target from Analysts

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been given an average recommendation of “Moderate Buy” by the eleven brokerages that are presently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $9.27.

A number of equities research analysts have recently weighed in on HCAT shares. Stifel Nicolaus dropped their target price on Health Catalyst from $10.00 to $5.00 and set a “hold” rating for the company in a report on Thursday, February 27th. KeyCorp upgraded shares of Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective for the company in a research note on Wednesday, January 8th. Stephens lowered their target price on shares of Health Catalyst from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Thursday, March 6th. Wells Fargo & Company cut their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Finally, Citigroup lowered their price objective on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research note on Friday, January 10th.

Insider Buying and Selling at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.51, for a total value of $39,119.59. Following the sale, the chief operating officer now directly owns 91,253 shares of the company’s stock, valued at $685,310.03. This trade represents a 5.40 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Benjamin Landry sold 13,827 shares of Health Catalyst stock in a transaction dated Thursday, March 6th. The shares were sold at an average price of $4.55, for a total value of $62,912.85. Following the completion of the transaction, the general counsel now owns 160,437 shares in the company, valued at approximately $729,988.35. This represents a 7.93 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 56,530 shares of company stock valued at $299,572. 2.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently added to or reduced their stakes in HCAT. Quantbot Technologies LP acquired a new position in shares of Health Catalyst during the fourth quarter worth $29,000. Group One Trading LLC increased its holdings in Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock worth $31,000 after purchasing an additional 2,260 shares in the last quarter. Quest Partners LLC bought a new position in Health Catalyst in the third quarter valued at about $34,000. Aquatic Capital Management LLC acquired a new stake in shares of Health Catalyst during the fourth quarter valued at about $63,000. Finally, Stoneridge Investment Partners LLC bought a new stake in shares of Health Catalyst during the fourth quarter worth about $77,000. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Price Performance

Shares of NASDAQ HCAT opened at $4.01 on Friday. The business’s 50 day moving average is $4.89 and its 200-day moving average is $6.72. The firm has a market cap of $281.55 million, a P/E ratio of -2.97 and a beta of 1.43. Health Catalyst has a 1-year low of $3.72 and a 1-year high of $9.24. The company has a current ratio of 1.41, a quick ratio of 1.41 and a debt-to-equity ratio of 0.32.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.